Showing results (1581-1590 of 1,951) with videos related to
Sort By:
Pageof 196
Current Atherosclerosis Reports|February 3, 2005
Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease riskVijay Nambi, Christie M BallantyneCurrent Atherosclerosis Reports|February 3, 2005
The impact of antidiabetic therapies on cardiovascular diseaseBrandy Panunti, Biju Kunhiraman, Vivian FonsecaCurrent Atherosclerosis Reports|February 3, 2005
Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosisClifford D L Folmes, Alexander S Clanachan, Gary D LopaschukCurrent Atherosclerosis Reports|February 3, 2005
Antioxidants and atherosclerosis: emerging drug therapiesJean-Claude TardifCurrent Atherosclerosis Reports|November 24, 2022
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular HealthPenny M Kris-Etherton, Philip A Sapp, Terrance M Riley, et al.Current Atherosclerosis Reports|January 6, 2023
How ANGPTL3 Inhibition Will Help Our Clinical Practice?Simone Bini, Daniele Tramontano, Ilenia Minicocci, et al.Current Atherosclerosis Reports|December 29, 2022
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate ContinuesSamuel C R Sherratt, Peter Libby, Matthew J Budoff, et al.Current Atherosclerosis Reports|June 30, 2022
COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next WaveAhmed A Kolkailah, Kayla Riggs, Ann Marie Navar, et al.Current Atherosclerosis Reports|June 28, 2021
Polygenic Risk Scores to Identify CVD Risk and Tailor Therapy: Hope or Hype?Charles A German, Michael D ShapiroCurrent Atherosclerosis Reports|June 19, 2021
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?Marcio H Miname, Viviane Z Rocha, Raul D SantosPageof 196